110 related articles for article (PubMed ID: 9080470)
1. Modulation of organ uptake of 11C-labelled L-DOPA.
Bergström M; Lu L; Marquez M; Fasth KJ; Bjurling P; Watanabe Y; Eriksson B; Långström B
Nucl Med Biol; 1997 Jan; 24(1):15-9. PubMed ID: 9080470
[TBL] [Abstract][Full Text] [Related]
2. Catechol-O-methyltransferase inhibition increases the uptake of 11C-3-(3,4-dihydroxyphenyl)-L-alanine in the rat pancreas.
Bergström M; Lu L; Marquez M; Moulder R; Jacobsson G; Ogren M; Eriksson B; Watanabe Y; Långström B
Scand J Gastroenterol; 1996 Dec; 31(12):1216-22. PubMed ID: 8976015
[TBL] [Abstract][Full Text] [Related]
3. Brain kinetics of L-[beta-11C]dopa in humans studied by positron emission tomography.
Hartvig P; Agren H; Reibring L; Tedroff J; Bjurling P; Kihlberg T; Långström B
J Neural Transm Gen Sect; 1991; 86(1):25-41. PubMed ID: 1751027
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
[TBL] [Abstract][Full Text] [Related]
5. Assessment of dopamine and its metabolites in the intracellular and extracellular compartments of the rat striatum after peripheral administration of L-[11C]dopa.
Miwa S; Gillberg PG; Bjurling P; Yumoto N; Odano I; Watanabe Y; Långström B
Brain Res; 1992 Apr; 578(1-2):122-8. PubMed ID: 1511268
[TBL] [Abstract][Full Text] [Related]
6. A comparison of 11C-labeled L-DOPA and L-fluorodopa as positron emission tomography tracers for the presynaptic dopaminergic system.
Torstenson R; Tedroff J; Hartvig P; Fasth KJ; Långström B
J Cereb Blood Flow Metab; 1999 Oct; 19(10):1142-9. PubMed ID: 10532639
[TBL] [Abstract][Full Text] [Related]
7. [carbonyl-11C]Desmethyl-WAY-100635 (DWAY) is a potent and selective radioligand for central 5-HT1A receptors in vitro and in vivo.
Pike VW; Halldin C; McCarron JA; Lundkvist C; Hirani E; Olsson H; Hume SP; Karlsson P; Osman S; Swahn CG; Hall H; Wikström H; Mensonidas M; Poole KG; Farde L
Eur J Nucl Med; 1998 Apr; 25(4):338-46. PubMed ID: 9553162
[TBL] [Abstract][Full Text] [Related]
8. In vivo assessment of decarboxylase inhibition or potentiation: urinary dopamine and L-dopa output after L-dopa administration.
Johnson RD; Ruthven CR; Goodwin BL; Sandler M
J Neural Transm; 1976; 38(3-4):181-91. PubMed ID: 956809
[TBL] [Abstract][Full Text] [Related]
9. In vivo microdialysis to determine the relative pharmacokinetics of drugs.
Nakashima M; Zhao MF; Nakashima MN; Sakurai M; Sasaki H; Matsuyama K; Ichikawa M
Biol Pharm Bull; 1996 Jul; 19(7):988-94. PubMed ID: 8839975
[TBL] [Abstract][Full Text] [Related]
10. Effect of high single doses of levodopa and carbidopa on brain dopamine and its metabolites: modulation by selective inhibitors of monoamine oxidase and/or catechol-O-methyltransferase in the male rat.
Männistö PT; Tuomainen P
Naunyn Schmiedebergs Arch Pharmacol; 1991 Oct; 344(4):412-8. PubMed ID: 1766471
[TBL] [Abstract][Full Text] [Related]
11. BIA 3-202, a novel catechol-O-methyltransferase inhibitor, enhances the availability of L-DOPA to the brain and reduces its O-methylation.
Parada A; Loureiro AI; Vieira-Coelho MA; Hainzl D; Soares-da-Silva P
Eur J Pharmacol; 2001 May; 420(1):27-32. PubMed ID: 11412836
[TBL] [Abstract][Full Text] [Related]
12. Liquid chromatographic analysis of brain homogenates and microdialysates for the quantification of L-[beta-11C]DOPA and its metabolites for the validation of positron emission tomography studies.
Lindner KJ; Hartvig P; Tedroff J; Ljungström A; Bjurling P; Långström B
J Pharm Biomed Anal; 1995 Apr; 13(4-5):361-7. PubMed ID: 9696544
[TBL] [Abstract][Full Text] [Related]
13. Modulatory effects of L-DOPA on D2 dopamine receptors in rat striatum, measured using in vivo microdialysis and PET.
Opacka-Juffry J; Ashworth S; Ahier RG; Hume SP
J Neural Transm (Vienna); 1998; 105(4-5):349-64. PubMed ID: 9720967
[TBL] [Abstract][Full Text] [Related]
14. β-asarone and levodopa coadministration increases striatal levels of dopamine and levodopa and improves behavioral competence in Parkinson's rat by enhancing dopa decarboxylase activity.
Huang L; Deng M; Zhang S; Lu S; Gui X; Fang Y
Biomed Pharmacother; 2017 Oct; 94():666-678. PubMed ID: 28787702
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
Nunes T; Machado R; Rocha JF; Fernandes-Lopes C; Costa R; Torrão L; Loureiro AI; Falcão A; Vaz-da-Silva M; Wright L; Almeida L; Soares-da-Silva P
Clin Ther; 2009 Oct; 31(10):2258-71. PubMed ID: 19922897
[TBL] [Abstract][Full Text] [Related]
16. Dopamine produced from L-DOPA is degraded by endogenous monoamine oxidase in neurons of the dorsal raphe nucleus of the rat: an immunohistochemical study.
Arai R; Karasawa N; Nagatsu I
Brain Res; 1996 May; 722(1-2):181-4. PubMed ID: 8813364
[TBL] [Abstract][Full Text] [Related]
17. L-3,4-dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential effects of monoamine oxidase A and B inhibitors.
Wachtel SR; Abercrombie ED
J Neurochem; 1994 Jul; 63(1):108-17. PubMed ID: 8207420
[TBL] [Abstract][Full Text] [Related]
18. Coadministration of β-asarone and levodopa increases dopamine in rat brain by accelerating transformation of levodopa: a different mechanism from Madopar.
Huang L; Deng M; Zhang S; Fang Y; Li L
Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):685-90. PubMed ID: 24910244
[TBL] [Abstract][Full Text] [Related]
19. Effects of monoamine oxidase and catechol-O-methyltransferase inhibition on dopamine turnover: a PET study with 6-[18F]L-DOPA.
Doudet DJ; Chan GL; Holden JE; Pate BD; Morrison KS; Calne DB; Ruth TJ
Eur J Pharmacol; 1997 Sep; 334(1):31-8. PubMed ID: 9346324
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of 6-11C-Methyl-m-Tyrosine as a PET Probe for Presynaptic Dopaminergic Activity: A Comparison PET Study with β-11C-l-DOPA and 18F-FDOPA in Parkinson Disease Monkeys.
Kanazawa M; Ohba H; Harada N; Kakiuchi T; Muramatsu S; Tsukada H
J Nucl Med; 2016 Feb; 57(2):303-8. PubMed ID: 26564319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
